On the other hand, ERBB2 mutations or amplifications have been identified in approximately 15–30% of breast cancers and 10–30% of gastric/gastroesophageal cancers and serve as prognostic and predictive biomarkers for those cancers [14]. This evidence concerns the gene ERBB2 and breast carcinoma.